S100A7 and neoplasm: S100A7 enhancement has been observed in early stages of tumor progression, as well as angiogenesis promotion by the transmembrane receptor for advanced glycation end products (RAGE) binding, evidenced on previous HUVEC studies19, as well as here (Supplementary Fig. 2).